Genflow Biosciences (GENF) Competitors GBX 1.10 -0.05 (-4.35%) As of 12:27 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsBuy This Stock GENF vs. SAR, OPTI, POLB, RLM, IMM, NSCI, SNG, OBD, BVX, and IXIShould you be buying Genflow Biosciences stock or one of its competitors? The main competitors of Genflow Biosciences include Sareum (SAR), OptiBiotix Health (OPTI), Poolbeg Pharma (POLB), Realm Therapeutics (RLM), ImmuPharma (IMM), NetScientific (NSCI), Synairgen (SNG), Oxford BioDynamics (OBD), BiVictriX Therapeutics (BVX), and IXICO (IXI). These companies are all part of the "biotechnology" industry. Genflow Biosciences vs. Sareum OptiBiotix Health Poolbeg Pharma Realm Therapeutics ImmuPharma NetScientific Synairgen Oxford BioDynamics BiVictriX Therapeutics IXICO Sareum (LON:SAR) and Genflow Biosciences (LON:GENF) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, community ranking, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability. Does the media favor SAR or GENF? In the previous week, Sareum had 2 more articles in the media than Genflow Biosciences. MarketBeat recorded 2 mentions for Sareum and 0 mentions for Genflow Biosciences. Sareum's average media sentiment score of 1.62 beat Genflow Biosciences' score of 0.00 indicating that Sareum is being referred to more favorably in the media. Company Overall Sentiment Sareum Very Positive Genflow Biosciences Neutral Does the MarketBeat Community favor SAR or GENF? Sareum received 82 more outperform votes than Genflow Biosciences when rated by MarketBeat users. CompanyUnderperformOutperformSareumOutperform Votes8266.13% Underperform Votes4233.87% Genflow BiosciencesN/AN/A Which has better earnings & valuation, SAR or GENF? Genflow Biosciences has lower revenue, but higher earnings than Sareum. Sareum is trading at a lower price-to-earnings ratio than Genflow Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSareumN/AN/A-£5.28M-£4.22-3.20Genflow Biosciences-£226.19K-16.58-£1.76M-£0.53-2.08 Do insiders & institutionals hold more shares of SAR or GENF? 9.2% of Genflow Biosciences shares are held by institutional investors. 5.0% of Sareum shares are held by company insiders. Comparatively, 64.2% of Genflow Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, SAR or GENF? Sareum has a beta of -1.08, suggesting that its stock price is 208% less volatile than the S&P 500. Comparatively, Genflow Biosciences has a beta of 2.37, suggesting that its stock price is 137% more volatile than the S&P 500. Is SAR or GENF more profitable? Genflow Biosciences has a net margin of 778.46% compared to Sareum's net margin of 0.00%. Genflow Biosciences' return on equity of -208.12% beat Sareum's return on equity.Company Net Margins Return on Equity Return on Assets SareumN/A -270.25% -113.80% Genflow Biosciences 778.46%-208.12%-58.66% SummaryGenflow Biosciences beats Sareum on 9 of the 13 factors compared between the two stocks. Remove Ads Get Genflow Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GENF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GENF vs. The Competition Export to ExcelMetricGenflow BiosciencesBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£3.75M£107.79M£5.59B£2.57BDividend YieldN/A3.78%5.37%4.95%P/E Ratio-2.083.1023.59140.01Price / Sales-16.584,194.85371.05262,597.18Price / Cash3.0012.7538.1727.90Price / Book4.4335.776.674.53Net Income-£1.76M-£91.48M£3.20B£5.76B7 Day Performance-26.67%-4.22%-5.58%0.34%1 Month Performance-41.30%58.78%-0.75%5.74%1 Year Performance-25.42%82.71%7.88%107.79% Genflow Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GENFGenflow BiosciencesN/AGBX 1.10-4.3%N/A-25.4%£3.75M£-226,187.99-2.085Gap DownHigh Trading VolumeSARSareumN/AGBX 13+8.3%N/A+19.6%£16.24MN/A-3.083,211Earnings ReportPositive NewsGap UpOPTIOptiBiotix HealthN/AGBX 16.44-3.3%N/A-21.5%£16.10M£590,009.23-5.201Gap DownPOLBPoolbeg PharmaN/AGBX 2.74-0.5%N/A-72.3%£14.06MN/A0.0012RLMRealm TherapeuticsN/AN/AN/AN/A£13.41M£501,919.00-0.66N/AIMMImmuPharmaN/AGBX 3.11-2.4%N/A+45.9%£13.24M£-71,310.29-5.3813Gap DownNSCINetScientificN/AN/AN/AN/A£12.81M£1.45M-486.3626SNGSynairgenN/AGBX 1.14+14.0%N/A-83.8%£11.15MN/A-0.6934Gap DownOBDOxford BioDynamicsN/AGBX 0.46-3.6%N/A-94.9%£8.64M£5.75M-0.0845Gap DownBVXBiVictriX TherapeuticsN/AN/AN/AN/A£8.25MN/A-250.0017Gap UpHigh Trading VolumeIXIIXICON/AGBX 8.50+1.5%N/AN/A£7.88M£11.50M-2.2089 Remove Ads Related Companies and Tools Related Companies SAR Competitors OPTI Competitors POLB Competitors RLM Competitors IMM Competitors NSCI Competitors SNG Competitors OBD Competitors BVX Competitors IXI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:GENF) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genflow Biosciences plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Genflow Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
